4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-056313
Chief Executive Officer sold 7,071 shares at an average $1.67 ($11,794)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Brainard Diana · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-11-17 | Sale : show line 1 in the form 10b5-1 | −2,689 | $1.63 | $4,386 | 879,288 | D |
| 2023-11-20 | Sale : show line 2 in the form 10b5-1 | −4,382 | $1.69 | $7,408 | 874,906 | D |
| Open-market sales · 7,071 sh · avg $1.67 · $11,794 | ||||||
Loading xslF345X05/doc4.xml…